Meduloc has raised $4 million in Series B funding as the orthopedic medical device company prepares to expand the clinical use of its fracture fixation technology. The financing comes as Meduloc moves from product development and regulatory clearance toward controlled commercialization of its platform.
The West Chester, Pennsylvania-based company announced the funding on August 6, 2026. GenHenn Capital led the round, with participation from Life Sciences Greenhouse Investments (LSGI), Ben Franklin Technology Partners of Southeastern Pennsylvania, Broad Street Angels, former Los Angeles Dodgers player Andre Ethier, and additional existing and new investors.
Funding to Support Meduloc’s Commercial Launch
Meduloc plans to use the new capital to support its controlled alpha launch, continue generating clinical evidence and build the commercial infrastructure needed to bring its fracture fixation platform to more surgeons and patients.
The company expects to begin the controlled alpha launch in early August 2026 with a selected group of orthopedic surgeons and institutions. The initial work will focus on building clinical experience across multiple fracture applications and gathering feedback from surgeons that can help guide future commercial expansion.
Sarah Sachinis, President and CEO of Meduloc, said the financing marks an important milestone as the company moves from product development and regulatory clearance into controlled commercialization.
The company also highlighted the support it has received from investors in Pennsylvania, particularly from the Greater Philadelphia region. LSGI, Ben Franklin Technology Partners of Southeastern Pennsylvania and Broad Street Angels participated in the financing.
Meduloc Develops Intramedullary Fracture Fixation Technology
Meduloc develops orthopedic devices designed to help treat small and long-bone fractures using internal fixation. The company was founded in 2016 by orthopedic specialists and Cor Medical Ventures to develop improved fixation options for small long bones.
Its technology uses an intramedullary approach, in which the implant is placed inside the bone to help stabilize a fracture. Meduloc describes its platform as minimally invasive and designed to provide fracture reduction and fixation control along with rotational stability.
The company says its device can be used for several applications involving the metacarpal, metatarsal, phalange, clavicle, radius, ulna and fibula. Its website also highlights a joint-preserving and soft-tissue-sparing surgical approach.
FDA Clearance Supports the Next Stage
Meduloc received FDA 510(k) clearance for its Intramedullary Fracture Fixation (IFF) System on October 29, 2025. The FDA lists the device under the name Meduloc Intramedullary Fracture Fixation (IFF) System and assigned it 510(k) number K250316. The FDA determined that the device was substantially equivalent to legally marketed predicate devices for the stated indications.
The FDA classifies the device as a Class II orthopedic device. The clearance documentation identifies the product under the regulation for smooth or threaded metallic bone fixation fasteners.
The company’s financing announcement describes the cleared system as a sterile, single-use system that uses a flexible nitinol intramedullary implant. Meduloc says the platform is intended for a range of upper- and lower-extremity long-bone fracture applications in adult and pediatric patients.
Company Moves From Development to Commercialization
The latest financing follows several development milestones for Meduloc. According to the company, it has secured issued patents, reached a stable product design through surgeon feedback, customer surveys and cadaveric testing, and established suppliers and manufacturers to support production.
The company is now shifting its attention toward real-world clinical experience and commercial preparation. Rather than immediately pursuing a broad launch, Meduloc plans to work with a selected group of surgeons and institutions during its controlled alpha phase.
This approach will allow the company to gather additional surgeon feedback while building clinical experience across different fracture applications. The information collected during this phase is expected to help Meduloc prepare for broader commercial expansion.
GenHenn Capital Leads the Series B
GenHenn Capital led the $4 million Series B round. The financing also brought together several Pennsylvania-based investors, including LSGI, Ben Franklin Technology Partners of Southeastern Pennsylvania and Broad Street Angels.
Andre Ethier, a former Los Angeles Dodgers player and Major League Baseball All-Star, also participated in the round. The financing included additional existing and new investors.
Bill Hagaman of GenHenn Capital said the firm sees potential in Meduloc’s fracture fixation technology and highlighted the company’s FDA clearance, early clinical experience and team as factors behind the investment.
Meduloc’s Next Focus
The $4 million Series B gives Meduloc additional resources as it enters a new stage of development. The company has already secured FDA clearance for its IFF System and is now preparing to build clinical experience through a controlled launch.
Its immediate focus will remain on the alpha launch, clinical evidence and commercial infrastructure. By working with selected orthopedic surgeons and institutions, Meduloc aims to gather practical feedback and experience before expanding the platform’s commercial reach.
For Meduloc, the latest funding represents a transition from developing and clearing its technology to putting the fracture fixation platform into broader clinical use. The company will now focus on building evidence, supporting surgeons and preparing for future expansion of its orthopedic device platform.
